The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

Episodios

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)
8 mar 2019· The Beacon (Video)
Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-responding patients with advanced NSCLC, weighing efficacy, potential toxicity, and cost concerns.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)
5 mar 2019· The Beacon (Video)
Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasingly complex patient care, along with the possible future role of artificial intelligence and telemedicine.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
¿Faltan episodios?

Pulsa aquí para actualizar resultados
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
28 dic 2018· The Beacon (Video)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
21 dic 2018· The Beacon (Video)
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
11 dic 2018· The Beacon (Video)
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
9 dic 2018· The Beacon (Video)
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
4 dic 2018· The Beacon (Video)
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and where these results fit into management of patients in this setting.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
2 dic 2018· The Beacon (Video)
Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
16 nov 2018· The Beacon (Video)
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
14 nov 2018· The Beacon (Video)
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
8 nov 2018· The Beacon (Video)
Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
6 nov 2018· The Beacon (Video)
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard of care in this setting.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
7 sep 2018· The Beacon (Video)
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a value in integrating more treatments into early combos.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
4 sep 2018· The Beacon (Video)
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at initial management, for limited progression on systemic therapy, or as local consolidation therapy.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
31 ago 2018· The Beacon (Video)
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/poor risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
29 ago 2018· The Beacon (Video)
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high or intermediate risk localized prostate cancer.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
27 ago 2018· The Beacon (Video)
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as presented by Wolfgang Fendler & colleagues at ASCO 2018.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
24 ago 2018· The Beacon (Video)
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with providing a context of results from similar prior research.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
22 ago 2018· The Beacon (Video)
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
20 ago 2018· The Beacon (Video)
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with this agent in patients with metastatic prostate cancer.
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Mostrar más

Episodios

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)

IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)

"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)

Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)

TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)

Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)

What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)

New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)

Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)

Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)